Shield Therapeutics PLC (LON:STX)

Shield Therapeutics PLC (LON:STX)


Share Price
115.00 p
Change
0.5 (0.44 %)
Market Cap
£134.65 m
Proactive Investors - Run By Investors For Investors

Shield Therapeutics PLC

Shield is a de-risked, commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs.  The Company’s clear purpose is to help its patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives.  The Group has a marketed product, Feraccru®, for the treatment of iron...

EPIC: STX
Market: LSE:STX
52-week High/Low: 118.00p / 24.00p
Sector: Pharma & Biotech
Market Cap: £134.65 m
Website: www.shieldtherapeutics.com
col 3
col 4
col 5
col 6

Big Picture – A Deep Dive Examination of Shield Therapeutics PLC


Shield Therapeutics PLC Timeline

Capital Network analyst Emma Ulker assesses recent progress made at Shield Therapeutics PLC (LON:STX) with its lead asset Feraccru. The drug's approved and marketed in Europe, with a US approval decision pending for July 27. Feraccru is an oral product absorbed in the gut. It's also an alternative for those unable...
Shield Therapeutics (LON:STX) is making excellent progress having reported two sets of new supportive clinical data on its lead product Feraccru, a low dose oral iron capsule. Feraccru is being positioned as an alternative therapy for patients with iron deficiency (ID) and iron deficiency...

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use